MyChesCo on MSN21h
Johnson & Johnson Advances Ulcerative Colitis Treatment with FDA Filing for TREMFYA® Subcutaneous Regimen
SPRING HOUSE, PA – Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval for a subcutaneous ...
GlobalData on MSN5d
J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis
The request is based on findings from the Phase III ASTRO study, which achieved the primary endpoint of clinical remission at ...
Zacks.com on MSN2d
J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC
If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as ...
FiercePharma9d
Cleanup for the IL-23 class in ulcerative colitis as new drugs 'rapidly gained significant momentum': report
The new ulcerative colitis (UC) triumvirate in Johnson & Johnson’s Tremfya, AbbVie’s Skyrizi and Eli Lilly’s Omvoh is rapidly ...
Johnson & Johnson Submits SBLA Seeking Approval Of TREMFYA In Ulcerative Colitis
Johnson & Johnson (JNJ) announced the submission of a supplemental Biologics License Application to the FDA seeking approval of a ...
JNJ seeks FDA approval of subcutaneous induction regimen of Tremfya
Johnson & Johnson announced the submission of a supplemental Biologics License Application to the U.S. FDA seeking approval of a ...
Benzinga.com1mon
Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease
The FDA approved Tremfya in September 2024 for moderately to severely active ulcerative colitis. The application for moderately to severely active Crohn's disease is currently under FDA review.
Healthline1mon
Side Effects of Tremfya: What You Need to Know
Tremfya (guselkumab) is a prescription drug that’s used to treat certain autoimmune conditions, including plaque psoriasis. Tremfya can cause side effects that range from mild to serious.